Dure geneesmiddelen * (extramuraal), de vergoeding in 2024
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|
| Rang 2024 |
ATC-code | |||||
| 1 | R07AX32 Ivacaftor met tezacaftor en elexacaftor (Kaftrio ®) | . | . | 117.333.000 | 126.886.400 | 126.024.400 |
| 2 | J06BA02 Immunoglobuline normaal intravasculair (Nanogam ®) | 72.297.700 | 74.482.700 | 93.570.100 | 101.393.000 | 104.615.900 |
| 3 | C10AX13 Evolocumab (Repatha ®) | 48.273.000 | 55.537.900 | 66.601.700 | 76.865.900 | 79.704.900 |
| 4 | C09DX04 Valsartan met sacubitril (Entresto ®) | 19.371.700 | 29.710.400 | 49.638.700 | 63.489.200 | 75.851.100 |
| 5 | R07AX02 Ivacaftor (Kalydeco ®) | 39.523.900 | 37.385.800 | 75.211.200 | 79.951.800 | 74.163.900 |
| 6 | C10AX14 Alirocumab (Praluent ®) | 41.041.300 | 47.665.500 | 58.487.900 | 65.795.800 | 72.356.800 |
| 7 | N07XX08 Tafamidis (Vyndaqel ®) | 3.879.500 | 3.545.500 | 26.845.200 | 41.813.800 | 58.269.700 |
| 8 | L04AX07 Dimethylfumaraat (Skilarence ®) | 51.348.100 | 51.535.400 | 52.725.500 | 51.481.500 | 48.703.000 |
| 9 | J05AR20 Emtricitabine met tenofoviralafenamide en bictegravir (Biktarvy ®) | 24.877.500 | 28.509.200 | 34.675.800 | 37.639.200 | 40.728.400 |
| 10 | L01EX09 Nintedanib (Ofev ®) | 12.000.100 | 17.404.500 | 23.152.600 | 28.706.600 | 32.628.100 |
| 11 | L04AD02 Tacrolimus (Prograft ®) | 33.073.300 | 27.851.900 | 29.054.600 | 30.295.900 | 31.817.300 |
| 12 | A09AA02 Multi-enzymen (lipase protease enz) (Creon ®) | 22.973.000 | 23.995.300 | 26.856.800 | 29.509.600 | 31.365.200 |
| 13 | A10BJ02 Liraglutide (Saxenda ®) | 11.639.700 | 9.275.700 | 17.715.000 | 26.717.900 | 30.199.000 |
| 14 | J05AR25 Lamivudine met dolutegravir (Dovato ®) | 6.208.300 | 11.691.500 | 17.155.100 | 22.279.000 | 27.944.100 |
| 15 | C02KX04 Macitentan (Opsumit ®) | 22.110.500 | 20.538.500 | 23.756.600 | 25.879.100 | 25.486.600 |
| 16 | J06BA01 Immunoglobuline normaal extravasculair (Cuvitru ®) | 15.835.400 | 16.638.900 | 20.157.400 | 21.034.800 | 22.021.900 |
| 17 | B02BX05 Eltrombopag (Revolade ®) | 11.898.100 | 13.246.000 | 16.713.100 | 19.157.900 | 19.218.600 |
| 18 | M09AX10 Risdiplam (Evrysdi ®) | . | . | . | 4.241.900 | 18.226.600 |
| 19 | H01CB03 Lanreotide (Somatuline ®) | 25.080.900 | 22.420.300 | 21.805.900 | 18.729.400 | 17.489.500 |
| 20 | J05AR18 Emtricitabine tenofovir alafenamide elvitegravir cobicista (Genvoya ®) | 27.958.800 | 23.652.300 | 21.694.200 | 19.139.000 | 17.207.200 |
| 21 | J06BA Normaal humaan immunoglobuline | 12.561.400 | 11.943.300 | 13.396.800 | 14.951.700 | 16.902.700 |
| 22 | L04AA40 Cladribine (Mavenclad ®) | 3.939.500 | 5.276.500 | 10.297.100 | 15.399.300 | 16.830.100 |
| Totaal | 505.891.700 | 532.307.100 | 816.844.300 | 921.358.700 | 987.755.000 | |